Search: onr:"swepub:oai:DiVA.org:oru-47313" >
Entacapone and pros...
Entacapone and prostate cancer risk in patients with Parkinson's disease
-
- Korhonen, Pasi (author)
- EPID Research Oy, Espoo, Finland
-
- Kuoppamäki, Mikko (author)
- Orion Pharma, Orion Corporation, Espoo, Finland
-
- Prami, Tuire (author)
- EPID Research Oy, Espoo, Finland
-
show more...
-
- Hoti, Fabian (author)
- EPID Research Oy, Espoo, Finland
-
- Christopher, Solomon (author)
- EPID Research Oy, Espoo, Finland
-
- Ellmen, Juha (author)
- Orion Pharma, Orion Corporation, Espoo, Finland
-
- Aho, Valtteri (author)
- Orion Pharma, Orion Corporation, Espoo, Finland
-
- Vahteristo, Mikko (author)
- Orion Pharma, Orion Corporation, Espoo, Finland
-
- Pukkala, Eero (author)
- Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland; School of Health Sciences, University of Tampere, Tampere, Finland
-
- Haukka, Jari (author)
- EPID Research Oy, Espoo, Finland
-
- Tuvblad, Catherine, 1968- (contributor)
- Örebro universitet,Institutionen för juridik, psykologi och socialt arbete,CAPS
-
show less...
-
(creator_code:org_t)
- 2015-01-16
- 2015
- English.
-
In: Movement Disorders. - Hoboken, USA : Wiley-Blackwell. - 0885-3185 .- 1531-8257. ; 30:5, s. 724-728
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background: The association between Parkinson’s disease (PD) and prostate cancer, both common in elderly men, is disputable. In the STRIDE-PD study, prostate cancer developed in 9 patients (3.7%) receiving levodopa/carbidopa with entacapone, a catechol-O-methyltransferase inhibitor, versus 2 cases (0.9%) without entacapone. The current pharmacoepidemiological study aimed to determine whether entacapone increases prostate cancer incidence or mortality in PD patients and whether cumulative exposure affects these rates.Methods: We performed a retrospective cohort study using population-wide health care registers with patientlevel linkage. Prostate cancer incidence and mortality were modeled by Cox’s proportional hazards models.Results and Conclusions: Use of entacapone with Ldopa/dopa decarboxylase inhibitor caused no increased risk of prostate cancer incidence (hazard ratio [HR]: 1.05; 95% confidence interval: 0.76-1.44) or mortality (0.93; 0.43-1.98). The HR for cumulative entacapone use of >360 days versus never-use was 0.82 (0.56-1.18) for prostate cancer incidence and 1.27 (0.60-2.72) for prostate cancer mortality.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- Entacapone
- evodopa
- prostate cancer
- pharmacoepidemiology
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Korhonen, Pasi
-
Kuoppamäki, Mikk ...
-
Prami, Tuire
-
Hoti, Fabian
-
Christopher, Sol ...
-
Ellmen, Juha
-
show more...
-
Aho, Valtteri
-
Vahteristo, Mikk ...
-
Pukkala, Eero
-
Haukka, Jari
-
Tuvblad, Catheri ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Movement Disorde ...
- By the university
-
Örebro University